Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19

S Malesevic, NA Sievi, P Baumgartner, K Roser… - Scientific Reports, 2023 - nature.com
… Long-Covid symptoms after a mild or moderate acute infection on HRQoL. In this observational
study, outpatients seeking counseling in the interdisciplinary Post-Covid … acute Covid-19

A structural equation model to examine the clinical features of mild‐to‐moderate COVID19: A multicenter Italian study

MR Barillari, L Bastiani, JR Lechien… - Journal of medical …, 2021 - Wiley Online Library
… features of mild-to-moderate coronavirus disease 2019 (COVID-19) … ) or laboratory-confirmed
COVID-19 infection were recruited. … A total of 294 patients with mild-to-moderate COVID-19

[HTML][HTML] Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

JR Lechien, CM Chiesa-Estomba, DR De Siati… - European Archives of …, 2020 - Springer
… Thus, we mainly included mild-to-moderate COVID-19 patients, defined as patients without
need of intensive cares. Since we focused on the prevalence of olfactory and gustatory …

Early use of remdesivir and risk of disease progression in hospitalized patients with mild to moderate COVID-19

M Falcone, LR Suardi, G Tiseo, C Barbieri, L Giusti… - Clinical Therapeutics, 2022 - Elsevier
… Preliminary data suggest that remdesivir may influence the course of COVID-19 according
COVID-19 progression in a homogeneous cohort of patients with mild to moderate COVID-19

Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial

…, K McTigue, E Shenkman, AF Hernandez, A COVID… - JAMA, 2023 - jamanetwork.com
… the use of repurposed drugs (a 50-mg, twice-daily dose of fluvoxamine for 10 days vs
placebo in this report) among nonhospitalized adults with mild to moderate COVID-19. …

Effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial

…, S Wilson, E Shenkman, AF Hernandez, A COVID… - Jama, 2022 - jamanetwork.com
… US with mild to moderate symptomatic COVID-19 is unknown. … Among outpatients with mild
to moderate COVID-19, treatment … of ivermectin in patients with mild to moderate COVID-19. …

Combined metabolic activators accelerates recovery in mild‐to‐moderate COVID19

O Altay, M Arif, X Li, H Yang, M Aydın… - Advanced …, 2021 - Wiley Online Library
… with mild-to-moderate COVID-19 and observed that combination therapy is safe and beneficial
in patients with mild-to-moderate COVID-19. … and safe treatment for COVID-19 patients. …

Bamlanivimab use in mild‐to‐moderate COVID19 disease: a matched cohort design

CJ Destache, SJ Aurit, D Schmidt… - … : The Journal of …, 2021 - Wiley Online Library
… is to prevent hospitalization associated with COVID-19 viral illness; however, this … COVID-19
cases and sought to determine if BAM treatment in patients with mild-to-moderate COVID-19

Real-world efficacy of regdanvimab on clinical outcomes in patients with mild to moderate COVID-19

T Kim, DH Joo, SW Lee, J Lee, SJ Lee… - Journal of Clinical …, 2022 - mdpi.com
… criteria defined in the Response Guidelines of COVID-19 by the Korean MOHW (version 10)
… A total of 166 patients with mild to moderate COVID-19 were enrolled in this study. Among …

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

M Ameres, S Brandstetter, AA Toncheva, M Kabesch… - Journal of …, 2020 - Springer
… co-morbidities indicate that mild-to-moderate COVID-19 is associated with increased
sNfL … that COVID-19 may affect the neuro-axonal integrity also in adults with a mild-to-moderate